Decheng Capital China Life Sciences USD Fund III, L.P. - 23 Sep 2022 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Role: 10%+ Owner
Signature: Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
Issuer symbol: N/A
Transactions as of: 23 Sep 2022
Net transactions value: +$14,700,000
Form type: 4
Filing time: 27 Sep 2022, 16:46:31 UTC
Previous filing: 30 Sep 2021
Next filing: 22 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALPN	Common Stock	Award	$4,700,002	+639,456	+14%	$7.35	5,347,744	23 Sep 2022	Direct	F1
transaction	ALPN	Common Stock	Award	$9,999,998	+1,360,544		$7.35	1,360,544	23 Sep 2022	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
F2	The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.

Content

The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.

The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.